{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    136,
    46,
    48,
    50,
    51,
    52,
    129,
    54,
    56,
    57,
    65,
    66,
    68,
    69,
    74,
    143,
    128,
    94,
    96,
    98,
    99,
    100,
    101,
    102,
    124,
    125,
    126,
    127
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Day 1 of Cycle 1"
      },
      {
        "id": "anchor_2",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Randomization \nDay"
      },
      {
        "id": "anchor_3",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline visit"
      },
      {
        "id": "anchor_5",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_6",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      },
      {
        "id": "anchor_collection_1",
        "definition": "24-hour collection period",
        "anchorType": "CollectionDay",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "24 hour urine"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_5",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_27",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_interval_10",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P6D",
        "exitCondition": "Disease progression",
        "sourceText": "6-week cycle"
      },
      {
        "id": "rep_cycle_9",
        "type": "Cycle",
        "cycleLength": "P6D",
        "sourceText": "6-week \ncycle"
      },
      {
        "id": "rep_cycle_19",
        "type": "Cycle",
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "rep_cycle_20",
        "type": "Cycle",
        "sourceText": "Cycle 2 Day 1"
      },
      {
        "id": "rep_cycle_21",
        "type": "Cycle",
        "sourceText": "Cycle 3 Day 1"
      },
      {
        "id": "rep_cycle_23",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_24",
        "type": "Cycle",
        "sourceText": "until death"
      },
      {
        "id": "rep_cycle_25",
        "type": "Cycle",
        "sourceText": "until \ndeath"
      },
      {
        "id": "rep_cycle_26",
        "type": "Cycle",
        "sourceText": "3 times a week"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "sourceText": "TREATMENT period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "FOLLOW-UP period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "90 days after"
      },
      {
        "id": "rep_window_11",
        "type": "Continuous",
        "sourceText": "3 days after"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "2 hours post"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "2 hours before"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "49 days after"
      },
      {
        "id": "rep_window_22",
        "type": "Continuous",
        "sourceText": "10 days after"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "24 hour urine"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P21D",
        "exitCondition": "Treatment-Related Toxicity",
        "sourceText": "5.4.6.4. Axitinib Dose Modifications, Avelumab Infusion Omissions, and Sunitinib Dose Modifications for Treatment-Related Toxicity"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P0D",
        "exitCondition": "End of Treatment/Withdrawal",
        "sourceText": "6.2. Treatment Period"
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "P0D",
        "exitCondition": "End of the Study",
        "sourceText": "8.2. Reporting Period"
      }
    ],
    "samplingConstraints": [
      {
        "id": "sampling_1",
        "activityId": "pk_sampling",
        "minPerWindow": 3,
        "timepoints": [
          "127",
          "7.3",
          "3"
        ],
        "sourceText": "Pharmacokinetic Samples ................................... 127 \n7.3.3. "
      }
    ],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "Crossover"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "TREATMENT_PERIOD",
          "END_OF_TREATMENT",
          "FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study",
          "Baseline",
          "Screening",
          "Follow-up Visits",
          "End of Treatment/Withdrawal",
          "Day 1"
        ],
        "sourceText": "[{'condition': 'Treatment-Related Toxicity (e.g., Grade 3 Proteinuria, IRR, or Immune-Related AE)', 'path': ['DOSE_MODIFICATION', 'INFUSION_OMISSION', 'TREATMENT_DISCONTINUATION']}, {'condition': 'Maximum Tolerated Dose (MTD) Exceeded', 'path': ['LOWER_DOSE_LEVEL_EXPLORATION']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 3"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse \nEvents",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2; SINGLE signals: 2"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 5; RECURRING signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Mri",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 14"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "Patient selection and screening criteria are performed once prior to randomization to determine eligibility."
      },
      {
        "activityId": "Tumor Assessments",
        "executionType": "Single",
        "rationale": "Tumor assessments are scheduled repeats at specific intervals throughout the study to monitor response."
      },
      {
        "activityId": "Safety Assessments",
        "executionType": "Single",
        "rationale": "Safety monitoring is conducted at each study visit to assess adverse events and patient health."
      },
      {
        "activityId": "Avelumab and Axitinib Dosing",
        "executionType": "Single",
        "rationale": "Treatment involves continuous repeated administration over defined cycles and time periods."
      },
      {
        "activityId": "Dose Modification for Toxicity",
        "executionType": "Single",
        "rationale": "Dosing adjustments or interruptions are conditional workflows triggered by specific safety events or decision points."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "Crossover"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "1. Visit Identifiers: All assessments should be performed prior to dosing with study treatments unless otherwise indicated.",
        "footnoteId": "fn_1",
        "structuredCondition": "activity.all.performedBefore(dosing)",
        "appliesToActivityIds": [
          "All assessments"
        ],
        "sourceText": "1. Visit Identifiers: All assessments should be performed prior to dosing with study treatments unle"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "2. Informed Consent: Must be obtained prior to undergoing any study-specific procedure.",
        "footnoteId": "fn_2",
        "structuredCondition": "informed_consent.obtained == true",
        "appliesToActivityIds": [
          "All study-specific procedures"
        ],
        "sourceText": "2. Informed Consent: Must be obtained prior to undergoing any study-specific procedure."
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "3. Medical/Oncological History: To include information on prior systemic adjuvant or neoadjuvant therapy regimens, surgery, and radiation therapy.",
        "footnoteId": "fn_3",
        "structuredCondition": "history.include(systemic_adjuvant, neoadjuvant, surgery, radiation)",
        "appliesToActivityIds": [
          "Medical History",
          "Oncological History"
        ],
        "sourceText": "3. Medical/Oncological History: To include information on prior systemic adjuvant or neoadjuvant the"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "4. Baseline Signs/Symptoms: To be recorded pre-dose on Cycle 1 Day 1.",
        "footnoteId": "fn_4",
        "structuredCondition": "recording.timing == 'pre-dose' && visit == 'C1D1'",
        "appliesToActivityIds": [
          "Baseline Signs/Symptoms"
        ],
        "sourceText": "4. Baseline Signs/Symptoms: To be recorded pre-dose on Cycle 1 Day 1."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "5. Physical Examination: Includes an examination of major body systems and weight.",
        "footnoteId": "fn_5",
        "structuredCondition": "exam.include(major_body_systems, weight)",
        "appliesToActivityIds": [
          "Physical Examination"
        ],
        "sourceText": "5. Physical Examination: Includes an examination of major body systems and weight."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "6. Contraception Check: Male patients with female partner of childbearing potential and female patients who are of childbearing potential will need to affirm that they meet the criteria for correct use of contraception.",
        "footnoteId": "fn_6",
        "structuredCondition": "patient.isChildbearingPotential == true || patient.partnerIsChildbearingPotential == true",
        "appliesToActivityIds": [
          "Contraception Check"
        ],
        "sourceText": "6. Contraception Check: Male patients with female partner of childbearing potential and female patie"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "14. Tumor Assessments: CT or MRI will include chest, abdomen and pelvis (CAP) at all time points.",
        "footnoteId": "fn_7",
        "sourceText": "14. Tumor Assessments: CT or MRI will include chest, abdomen and pelvis (CAP) at all time points."
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-Free Survival (PFS) in PD-L1 Positive Patients",
        "endpointType": "Primary",
        "inputs": [
          "PD-L1 expression status",
          "Date of randomization",
          "Date of first documentation of objective tumor progression",
          "Date of death (any cause)"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until disease progression or death"
        },
        "algorithm": "min(Date of progression, Date of death) - Date of randomization",
        "successCriteria": "Avelumab + axitinib superior to sunitinib monotherapy in PD-L1 positive patients",
        "sourceText": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients"
      },
      {
        "id": "ep_2",
        "name": "Primary: Overall Survival (OS) in PD-L1 Positive Patients",
        "endpointType": "Primary",
        "inputs": [
          "PD-L1 expression status",
          "Date of randomization",
          "Date of death (any cause)"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death"
        },
        "algorithm": "Date of death - Date of randomization",
        "successCriteria": "Avelumab + axitinib superior to sunitinib monotherapy in PD-L1 positive patients",
        "sourceText": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Progression-Free Survival (PFS) in Unselected Patients",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of first documentation of objective tumor progression",
          "Date of death (any cause)"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until disease progression or death"
        },
        "algorithm": "min(Date of progression, Date of death) - Date of randomization",
        "successCriteria": "Avelumab + axitinib superior to sunitinib monotherapy in patients unselected for PD-L1 expression",
        "sourceText": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS in the first-line treatment of patients with aRCC unselected for PD-L1 expression."
      },
      {
        "id": "ep_4",
        "name": "Secondary: Overall Survival (OS) in Unselected Patients",
        "endpointType": "Secondary",
        "inputs": [
          "Date of randomization",
          "Date of death (any cause)"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Until death"
        },
        "algorithm": "Date of death - Date of randomization",
        "successCriteria": "Avelumab + axitinib superior to sunitinib monotherapy in patients unselected for PD-L1 expression",
        "sourceText": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging OS in the first-li"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "PFS (Progression-Free Survival)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Progression",
          "Date of Death"
        ],
        "derivationRule": "Time from randomization to the first documentation of objective tumor progression or to death from any cause, whichever occurs first.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Continuous",
        "imputationRule": "Censoring rules as per RECIST 1.1",
        "unit": "Months"
      },
      {
        "id": "dv_2",
        "name": "OS (Overall Survival)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of Randomization",
          "Date of Death"
        ],
        "derivationRule": "Time from randomization to death from any cause.",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Continuous",
        "imputationRule": "Censored at the date of last contact",
        "unit": "Months"
      },
      {
        "id": "dv_3",
        "name": "Objective Response Status",
        "variableType": "Categorical",
        "sourceVariables": [
          "Target Lesions",
          "Non-target Lesions",
          "New Lesions"
        ],
        "derivationRule": "Derived from changes in target, non-target, and new lesions according to RECIST 1.1 (CR, PR, SD, PD).",
        "baselineDefinition": "Measurable disease at baseline assessment",
        "baselineVisit": "Screening",
        "analysisWindow": "Every 6-8 weeks",
        "imputationRule": "Non-evaluable (NE) if assessments are missing"
      },
      {
        "id": "dv_4",
        "name": "Anti-Drug Antibody (ADA) Status",
        "variableType": "Categorical",
        "sourceVariables": [
          "Anti-avelumab antibody titer"
        ],
        "derivationRule": "Characterization of samples as positive or negative for ADA; positive samples may undergo Neutralizing Antibody (Nab) characterization.",
        "baselineDefinition": "Pre-dose sample on Day 1 of Cycle 1",
        "baselineVisit": "Cycle 1 Day 1",
        "analysisWindow": "Pre-dose at specified cycles up to Cycle 16",
        "imputationRule": "Missing data excluded from prevalence/incidence calculation"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Treatment Period",
        "End Of Treatment",
        "Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Treatment Period",
          "trigger": "Progress to Treatment Period"
        },
        {
          "fromState": "Treatment Period",
          "toState": "End Of Treatment",
          "trigger": "Progress to End Of Treatment"
        },
        {
          "fromState": "End Of Treatment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment Period",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "End Of Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Treatment Period": "TREATMENT_PERIOD",
        "End Of Treatment": "END_OF_TREATMENT",
        "Follow Up": "FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Sunitinib PO",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "4 weeks",
        "sourceText": "itinib, or single-agent avelumab, or single-agent axitinib provided that the treating physician has determined that the benefit/risk for doing so is favorable. In Arm B, patients will receive: • Sunit"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Avelumab (MSB0010718C)",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "mg/kg",
            "description": "Starting dosing regimen"
          }
        ],
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Infusion omissions for treatment-related toxicity",
          "Management of infusion-related reactions"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Axitinib (INLYTA, AG-013736)",
        "frequency": "BID",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg",
            "description": "Standard starting dose"
          }
        ],
        "durationDescription": "Continuous",
        "titrationSchedule": "Intrapatient dose escalation and dose reduction allowed based on safety and tolerability",
        "doseModifications": [
          "Dose reduction for treatment-related toxicity",
          "Management of hypertension"
        ]
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Sunitinib Malate (SUTENT, SU011248)",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "mg",
            "description": "Starting dose"
          }
        ],
        "durationDescription": "4 weeks on, 2 weeks off",
        "doseModifications": [
          "Dose modifications for treatment-related toxicity",
          "Management of hypertension"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_2",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 28,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "6.1. Screening .......................................................................................................... 118 6.1.1. Tumor Biospecimens ................................................"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "5.8.2. Hematopoietic Growth Factors .............................................................. 115 5.8.3. Concomitant Surgery ......................................................................"
      },
      {
        "id": "visit_3",
        "visitName": "End of Treatment",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "6.3. End of Treatment/Withdrawal and Follow-up Visits .......................................... 119 6.4. End of the Study ............................................................................."
      },
      {
        "id": "visit_9",
        "visitName": "Baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "4. Baseline Signs/Symptoms: To be recorded pre-dose on Cycle 1 Day 1. Patients will be asked about any signs and symptoms experienced within the 14 days prior to randomization. 5. Physical Examination"
      },
      {
        "id": "visit_11",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "patients from screening until the end of study visit will be recorded on the CRF. Concomitant medications and treatments, including herbal supplements, will be recorded from 28 days prior to the start"
      },
      {
        "id": "visit_llm_8",
        "visitName": "End of Treatment/Withdrawal",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_5",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Treatment",
        "sourceText": "Randomization Day 1"
      },
      {
        "id": "visit_10",
        "visitName": "Day 5",
        "targetDay": 5,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "17. Follow-up for Axitinib/Sunitinib Dosing Compliance: Follow-up by telephone will be done on Day 5 of the first cycle to confirm patient understanding and compliance with dosing instructions. Axitin"
      },
      {
        "id": "visit_7",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Treatment",
        "sourceText": "Day 15 (±3 days) Day 29"
      },
      {
        "id": "visit_8",
        "visitName": "Day 29",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "epoch": "Treatment",
        "sourceText": "Day 29 (±3 days) Day 1"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Cycle 2+ Day 1",
        "targetDay": 43,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 7,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Cycle 2+ Day 15",
        "targetDay": 57,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 9,
        "epoch": "Treatment"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Cycle 2+ Day 29",
        "targetDay": 71,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 11,
        "epoch": "Treatment"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "6.3. End of Treatment/Withdrawal and Follow-up Visits .......................................... 119 6.4. End of the Study ............................................................................."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "ecog ps (0 versus 1) \nand region (united states vs canada/western europe vs the rest of the world)"
        },
        {
          "id": "strat_llm_1",
          "name": "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
          "categories": [
            "0",
            "1"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "MSB0010718C, AG-013736 \nB9991003  \nFinal Protocol Amendment 8, 03 January 2020 \n \n \n \n \nPage 30 \n \n \n  \n  \n \n \n  \n  \n \n \n  \n \n \n \n \n  \n \n \n \n \n \n \n  \n \n \n  \n \n \n \n \n \n \n \n \n \n \n f \n \n \n \n \n \n \n \n \n \n "
    }
  }
}